📰 Full Story
HC Wainwright & Co. reiterated a "Buy" rating and a $100 price target on Immunocore Holdings PLC (IMCR) in a research note dated Feb. 4, 2026, and published by MarketBeat on Feb. 5.
Analyst Patrick Trucchio also provided a long-term FY2030 earnings forecast of $11.26 per share.
The reaffirmation comes amid varied Wall Street coverage: UBS set a $55 target (Jan. 7), Wells Fargo initiated an overweight at $60 (Oct. 31, 2025), Morgan Stanley holds an equal-weight with a $36 target (Nov. 10, 2025), while Zacks and Weiss Ratings have offered divergent views.
MarketBeat data shows a consensus price target near $60.40 and an average analyst view of "Moderate Buy." Immunocore, a clinical- and commercial-stage biotech with approved KIMMTRAK for metastatic uveal melanoma, reported quarterly EPS of $0.02 and revenue of $103.7 million on Nov. 6, 2025, with revenue up 29.2% year-on-year.
IMCR shares opened at $31.50 on Feb. 5, with a 52‑week range of $23.15–$40.71 and institutional ownership around 84.5%. Analysts’ one-year targets span $37 to $100, underscoring wide valuation dispersion tied to pipeline and commercial execution risks.























💬 Commentary